ProDGNE Kick-off Webinar 3rd June 2021, 6pm CET

3 June 2021

GNE Myopathy is a rare genetic (autosomal recessive) disorder that causes progressive skeletal muscle atrophy and weakness. Previous names include hereditary inclusion body myopathy (HIBM), inclusion body myopathy type 2 (IBM2) or Nonaka myopathy. GNE myopathy results from mutations in a gene called GNE, which is responsible for a step in the production of a sugar called sialic acid.

Symptoms of the disease usually appear between 20 and 40 years of age and include foot drop and difficulty walking. The disease slowly affects other muscles of the arms and legs and patients typically start using a wheelchair one or two decades late.

ProDGNE ( is a research project aiming to develop innovative treatments for this disease and it has obtained Horizon 2020 co-funding under the EJPRD call on preclinical research. The project will unify European and Canadian efforts to develop an innovative therapeutic approach for GNE Myopathy.

Learn more about ProDGNE

Follow ProDGNE on twitter

Further details

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit